MedTrace Logo

Express Testing and Same-day Initiation of PrEP Study

NCT05690815 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 816

Last updated 2024-03-29

No results posted yet for this study

Summary

This study is an observational cohort study to measure the impact of express testing and same-day initiation of Pre-Exposure Prophylaxis (PrEP) on outcomes related to the PrEP cascade. The investigators expect that same day initiation for PrEP will improve PrEP uptake. The investigators hypothesize that baseline HIV test positivity will be higher than that of general testing for gbMSM in Ontario. This is a key indicator to determine whether this targeted approach is able to access the highest risk population.

Conditions

  • HIV Prevention

Interventions

DRUG

Descovy

Descovy is a once-daily prescription medicine for adults and adolescents at risk of HIV. It helps lower the chances of getting HIV through sex. In this study, patients at risk of acquiring HIV will be screened for HIV and those that are HIV-negative will be initiated on PrEP within 24 hours.

Sponsors & Collaborators

Principal Investigators

  • Kevin S Woodward, MD · HQ Health HubToronto

Eligibility

Min Age
16 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-24
Primary Completion
2024-11-30
Completion
2024-11-30
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05690815 on ClinicalTrials.gov